Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM0306 in R/R B-NHL
NCT04746131Phase 1Suspended
- Sponsor
- ImmuneOnco
- Start
- Jan 2021
- Primary completion
- Apr 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMM0306S in B-cell non-Hodgkin lymphoma, sponsored by ImmuneOnco. Primary endpoint: Maximum Tolerated Dose at 52 weeks. Started Jan 2021; status: suspended.
02
Drugs
IMM0306S
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04746131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04746131.